Independent
Tenure on this board
1.7 yrs
Also a director at
Bruker Corp (BRKR)
Meeting calendar
NEOG · Annual meeting · Thursday, October 23, 2025
Neogen Corp
4 nominees · 3 ballot items.
Election of four Class II directors; advisory approval of named executive officers' compensation; and ratification of BDO USA P.C. as Neogen's independent registered public accounting firm for the 2026 fiscal year.
Market cap
$2.0B
1Y TSR
+71.5%
Board grade
C-
Record date
Aug 26, 2025
Filing
DEF 14A
Meeting concluded · Oct 23, 2025
Follow how the vote landed and what changed on Neogen Corp’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot3
- 1
Election of Directors
ManagementBoard: FORElection of four Class II directors to serve for three-year terms or until their successors have been duly qualified and elected.
- 2
To Approve, On An Advisory Basis, The Compensation of Named Executive Officers
ManagementBoard: FORAdvisory vote to approve, on an advisory basis, the compensation of Neogen's named executive officers as disclosed in this Proxy Statement.
- 3
Ratification of the Appointment of the Company’s Independent Registered Public Accounting Firm
ManagementBoard: FORRatify the appointment of BDO USA P.C. as the Company’s independent registered public accounting firm for the fiscal year ending May 31, 2026.
Director elections
Nominees on the ballot4
Mikhael Nassif
Not independent
Tenure on this board
New nominee
Independent
Tenure on this board
0.7 yrs
Independent
Tenure on this board
1.1 yrs
Also a director at
Analog Devices Inc (ADI)
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | BlackRock, Inc. | 10.6% | 23,079,533 | $214M |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 5.9% | 12,832,264 | $119M |
| 3 | T. Rowe Price Investment Management, Inc. | 4.7% | 10,162,715 | $94M |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 4.4% | 9,565,046 | $89M |
| 5 | DIMENSIONAL FUND ADVISORS LP | 4.1% | 8,950,150 | $83M |
| 6 | ING GROEP NV | 4.1% | 8,904,300 | $83M |
| 7 | STATE STREET CORP | 3.9% | 8,590,344 | $80M |
| 8 | MACKENZIE FINANCIAL CORP | 3.6% | 7,803,226 | $72M |
| 9 | Neuberger Berman Group LLC | 3.6% | 7,751,718 | $72M |
| 10 | BlackRock, Inc. | 3.0% | 6,501,793 | $60M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Neogen Corp’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Anaptysbio IncANAB
Annual meeting·Aug 11, 2026·$2.0B
Trulieve Cannabis CorpTRLV
Special meeting·Aug 5, 2026·$1.9B
Prestige Consumer Healthcare IncPBH
Annual meeting·Aug 4, 2026·$2.2B
Avanos Medical IncAVNS
Special meeting·Jul 22, 2026·$1.2B
Esperion Therapeutics IncESPR
Special meeting·Jul 8, 2026·$814M
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$734M
Reference
Frequently asked questions
- When is the Neogen Corp 2025 annual meeting?
- Neogen Corp (NEOG) holds its 2025 annual shareholder meeting on Thursday, October 23, 2025.
- What is the record date for the Neogen Corp 2025 meeting?
- The record date for the Neogen Corp 2025 meeting is Tuesday, August 26, 2025. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Neogen Corp's 2025 meeting?
- The board is presenting 4 director nominees at the Neogen Corp 2025 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Neogen Corp 2025 meeting?
- Shareholders will vote on 3 proposals at the Neogen Corp 2025 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.